Bullseye Investor
Short-term horizon

Insulet: Growth Story With 100% Upside

Insulet Corporation (NASDAQ:PODD) sells the only commercially available insulin infusion system OmniPod. OmniPod is a handheld device that consists of a pod, which can be worn on many parts of the body to hold and deliver insulin. The device wirelessly programs the Pod and calculates suggested doses with the help of a built-in blood glucose meter. The company has agreements with Abbott (NYSE:ABT) and DexCom (NASDAQ:DXCM) to integrate its OmniPod Personal Diabetes Manager. Neighborhood Diabetes was acquired by PODD in 2011 for $63 mn. The deal gave access to 15,000+ insulin-dependent customers. PODD gained FDA approval in January 2005 and has ~38,500 patients using the system as of December 31, 2012. Before going into...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details